Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 491-496

  Lambert Niclot, Sidonie ^a   Flandre, Philippe ^a   Canestri, Ana ^a   Peytavin, Gilles ^b   Blanc, Christine ^a   Agher, Rachid ^a   Soulié, Cathia ^a   Wirden, Marc ^a   Katlama, Christine ^a   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RNA, VIRAL; SELECTION (GENETICS); SULFONAMIDES; TREATMENT FAILURE;

EID: 38649088910     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00909-07     Document Type: Article

References (32)

1. Baxter, J. D., J. M. Schapiro, C. A. Boucher, V. M. Kohlbrenner, D. B. Hall, J. R. Scherer, and D. L. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologie response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
2. Clotet, B., N. Bellos, J. M. Molina, D. Cooper, J. C. Goffard, A. Lazzarin, A. Wohrmann, C. Katlama, T. Wilkin, R. Haubrich, C. Cohen, C. Farthing, D. Jayaweera, M. Markowitz, P. Ruane, S. Spinosa-Guzman, and E. Lefebvre. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
3. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, et al. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
4. Delaugerre, C., P. Flandre, M. L. Chaix, P. Dellamonica, F. Raffi, H. Jäger, D. Schürmann, Ngo M. Van Norton, I. Cohen Codar, J. F. Delfraissy, and C. Rouzioux. 2007. XVI Int. HIV Drug Resistance Workshop, abstr. 75.
5. Delaugerre, C., D. Mathez, G. Peytavin, H. Berthe, K. Long, T. Galperine, and P. de Truchis. 2007. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS 21:1210-1213.
6. De Meyer, S., H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
7. De Meyer, S., A. Hill, I. De Baere, L. Rimsky, H. Azijn, B. VanBaelen, et al. 2006. 13th Conf. Retrovir. Opportunistic Infect., abstr. TUPE 0083.
8. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133:35-39.
9. Haubricb, R., D. Berger, P. Chiliade, A. Colson, M. Conant, J. Gallant, T. Wilkin, J. Nadler, G. Pierone, M. Saag, B. van Baelen, and E. Lefebvre. 2007. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 21:F11-F18.
10. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 283:2417-2426.
11. Ives, K. J., H. Jacobsen, S. A. Galpin, M. M. Garaev, L. Dorrell, J. Mous, K. Bragman, and J. N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771-779.
12. Jacobsen, H., M. Hanggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. 173:1379-1387.
13. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
14. Katlama, C., R. Esposito, J. M. Gatell, J. C. Goffard, B. Grinsztejn, A. Pozniak, J. Rockstroh, A. Stoehr, N. Vetter, P. Yeni, W. Parys, and T. Vangeneugden. 2007. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 21:395-402.
15. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
16. King, N. M., M. Prabu-Jeyabalan, E. A. Nalivaika, P. Wigerinck, M. P. de Bethune, and C. A. Schiffer. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021.
17. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-1690.
18. Lefebvre, E., M. P. de Bethune, S. De Meyer, T. Vangeneugden, M. De Pauw, M. Cefalone, et al. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother, abstr. H-1387.
19. Maguire, M., D. Shortino, A. Klein, W. Harris, V. Manohitharajah, M. Tisdale, R. Elston, J. Yeo, S. Randall, F. Xu, H. Parker, J. May, and W. Snowden. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:731-738.
20. Marcelin, A. G., D. Affolabi, C. Lamotte, H. A. Mohand, C. Delaugerre, M. Wirden, D. Voujon, P. Bossi, N. Ktorza, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, and V. Calvez. 2004. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. J. Med. Virol. 74:16-20.
21. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
22. Mo, H., M. S. King, K. King, A. Molla, S. Brun, and D. J. Kempf. 2005. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79:3329-3338.
23. Mo, H., N. Parkin, K. D. Stewart, L. Lu, T. Dekhtyar, D. J. Kempf, and A. Molla. 2007. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob. Agents Chemother. 51:732-735.
24. Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antivir. Res. 39:1-23.
25. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
26. Nijhuis, M., A. M. Wensing, W. Bierman, D. de Jong, W. J. M. van Rooyen, R. Kagan, C. Jaspers, K. Schurink, L. Lu, T. Pilot-Mathias, A. Molla, M. A. van Agtmael, and C. A. B. Boucher. 2007. XVI Int. HIV Drug Resist. Workshop, abstr. 127.
27. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
28. Parkin, N. T., S. G. Deeks, M. T. Wrin, J. Yap, R. M. Grant, K. H. Lee, D. Heeren, N. S. Hellmanna, and C. J. Petropoulos. 2000. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 14:2877-2887.
29. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
30. Rhee, S. Y., W. J. Fessel, A. R. Zolopa, L. Hurley, T. Liu, J. Taylor, D. P. Nguyen, S. Slome, D. Klein, M. Horberg, J. Flamm, S. Follansbee, J. M. Schapiro, and R. W. Shafer. 2005. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis. 192:456-465.
31. Rhee, S. Y., J. Taylor, G. Wadhera, A. Ben-Hur, D. L. Brutlag, and R. W. Shafer. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103:17355-17360.
32. Swanstrom, R., and J. Erona. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.